Clinical Trials

Enhanced Rehab for Stroke Doubles Movement Recovery

 A novel therapy technique invented by researchers at The University of Texas at Dallas has been shown in a pilot study to double the rate of upper limb recovery in stroke patients, a leap forward in treating the nearly 800,000 Americans who suffer strokes each year. The results of the study, funded by UT Dallas spinoff company MicroTransponder of Austin, Texas, were published Sept. 27 in the journal Stroke. The findings
Breast Cancer cancer Cancer Discovery Clinical Trials

Researchers to Test Novel Drug Combination Against Toughest Breast Cancers

Phase I clinical trial will combine standard chemotherapy with cirmtuzumab, a drug that has shown promise against a variety of cancer types Researchers at University of California San Diego School of Medicine have launched a phase Ib clinical trial to assess the safety and tolerability of cirmtuzumab, in combination with standard chemotherapy, to treat metastatic or locally advanced breast cancer that cannot be surgically removed. Cirmtuzumab is a novel monoclonal antibody
Breast Cancer

Cancer Center of Kansas to Study Novel Cancer Immunotherapy in Advanced Breast Cancer

The Cancer Center of Kansas (CCK) has been added as a new clinical trial site and will be part of an ongoing, multicenter, Phase IIa study of Bria-IMT™ (listed in ClinicalTrials.gov as NCT03066947) in advanced breast cancer, as well as the rollover combination study of  BriaCell Therapeutic's Bria-IMT™ with pembrolizumab or ipilimumab (listed in ClinicalTrials.gov as NCT03328026). Dr. Shaker R. Dakhil, Board certified in Medical Oncology and Internal Medicine, will
Clinical Trials

Eating Crickets Can Be Good for Your Gut, According to New Clinical Trial

Valerie Stull was 12 when she ate her first insect. “I was on a trip with my parents in Central America and we were served fried ants,” she says. “I remember being so grossed out initially, but when I put the ant in my mouth, I was really surprised because it tasted like food — and it was good!” Today, Stull, a recent doctoral graduate of the University of Wisconsin–Madison Nelson
Biotechnology

CRISPR/Cas9 gene editing scissors are less accurate than we thought, but there are fixes

by Gaetan Burgio CRISPR gene editing technology is revolutionizing medicine and biology. This technique allows scientists to edit DNA with more precision and greater ease than previous gene editing technology. But a new study has called into question the precision of the technique. The hope for gene editing is that it will be able to cure and correct diseases. To date, many successes have been reported, including curing deafness in
Breast Cancer

Potential new surgical options for women with multiple ipsilateral breast cancer

A new multi-institutional clinical trial compared outcomes of women with multiple ipsilateral breast cancer, or more than one site of disease in the same breast, who underwent breast-conserving surgery, with outcomes of those who converted to mastectomy. Out of 198 eligible women in the trial, 184 (92.9%) successfully completed breast-conserving surgery, 134 of those with a single operation. These findings have just been published online first in Annals of Surgical
cancer Cancer Discovery Clinical Trials

Magnetic Nanoparticles Leap From Lab Bench to Breast Cancer Clinical Trials

 Sandia National Laboratories materials chemist Dale Huber has been working on the challenge of making iron-based nanoparticles the exact same size for 15 years. Now, he and his long-term collaborators at Imagion Biosystems will use these magnetic nanoparticles for their first breast cancer clinical trial later this year. The nanoparticles stick to breast cancer cells, allowing the detection and removal of even small metastases. Imagion Biosystems and Huber have been working together
Biotechnology cancer rare diseases

Study Reports Possible Novel Method for Stopping Untreatable Pediatric Brain Cancer

Researchers used an experimental molecular therapy in preclinical laboratory tests to effectively treat several types of deadly pediatric brain cancer and now propose advancing the treatment to clinical testing in children. Scientists at the Cincinnati Children’s Cancer and Blood Diseases Institute report in the journal Molecular Cancer Therapeutics testing the small molecule 6-thio-2’deoxyguanosine (6-thio-dG) in brain cancer stem cells derived from tumor cells donated by patients. Researchers also tested the
Biotechnology Clinical Trials Pharmaceuticals Prescriptions Prodrug

IU Research Suggests Failed Osteoarthritis Drug Could Get New Life as Opioid-Addiction Treatment

A new study from Indiana University suggests that a drug proven safe for use in people may prevent opioid tolerance and physical dependence when used in combination with opioid-based pain medications. Researchers in the Linda and Jack Gill Center for Biomolecular Science at IU Bloomington have discovered that a compound previously tested to treat osteoarthritis pain appears to block neuropathic pain and decrease signs of opioid dependence. The work is reported in the
cancer Clinical Trials

Phase I Clinical Trial Shows Some Promise for Investigational Drug for Melanoma

An investigational compound designed to block a hyperactive cell growth signal in advanced melanoma and other cancers has shown some promise in an early-stage clinical trial, researchers at the University of North Carolina Lineberger Comprehensive Cancer Center and other institutions have reported. In JCI Insight, UNC Lineberger’s Stergios Moschos, MD, and colleagues published the results of a phase I, multi-institution clinical trial for an investigational treatment for melanoma and other
Gene Therapy Pharmaceutical Business News

Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for Gene Therapy in Epidermolysis Bullosa

Gene therapy developer, Abeona Therapeutics, announced that the FDA has granted Regenerative Medicine Advanced Therapy designation to EB-101, a gene-corrected autologous cell therapy product for patients with recessive dystrophic epidermolysis bullosa (RDEB). Abeona`s EB-101 product is an autologous, ex-vivo gene-corrected cell therapy in which the COL7A1 gene is inserted into a patient`s own skin cells (keratinocytes) for the treatment of the underlying disease in Recessive Dystrophic Epidermolysis Bullosa. The EB-101 program has
Biotechnology cancer Cell Therapy Clinical Trials

Researchers repurpose immune-activating cytokine to fight breast cancer

The most lethal form of breast cancer could have a new treatment option, according to new research out of the Case Comprehensive Cancer Center at Case Western Reserve University School of Medicine. In the Proceedings of the National Academy of Sciences, researchers showed triple-negative breast cancer cells are highly vulnerable to interferon-β--a potent antimicrobial that also activates the immune system. The new study shows interferon-β impairs breast cancer cells' ability
Biotechnology cancer Cancer Discovery Clinical Trials

Promising new treatment for rare pregnancy cancer leads to remission in patients

Three out of four patients with the cancerous forms of gestational trophoblastic disease (GTD) went into remission after receiving the immunotherapy drug pembrolizumab in a clinical trial carried out by researchers at Imperial College London. The trial, which took place at Charing Cross Hospital, part of Imperial College Healthcare NHS Trust, is the first to show that pembrolizumab can be used to successfully treat women with GTD. The team hopes
Biotechnology Clinical Trials

No cardiovascular disease reduction with intensive blood pressure lowering treatment

Blood pressure lowering treatment does not reduce death or cardiovascular disease in healthy individuals with a systolic blood pressure below 140. This is shown in a systematic review and meta-analysis from Umeå University. The results, published in JAMA Internal Medicine, support current guidelines and contradict the findings from the Systolic Blood Pressure Intervention Trial (SPRINT). Blood pressure treatment goals have been intensively debated since the publication of the SPRINT study
Biotechnology cancer Clinical Trials Immunotherapies

For cancer patients with HIV, immunotherapy appears safe

A new category of immunotherapies called checkpoint inhibitors that has been highly effective against many different cancers appears safe to use in patients with both advanced malignancies and HIV, a population excluded from earlier trials of such therapies, according to an early-phase trial. Study Principal Investigator, Dr. Thomas Uldrick of the HIV & AIDS Malignancy Branch at the National Cancer Institute, will present late breaking results from the first 17
Biotechnology cancer Cell Therapy Clinical Trials

Cancer trial led by University of Minnesota Medical School’s Dr. Clark Chen shows promise

New data from a Phase I clinical trial led by Clark Chen, M.D., Ph.D., Lyle French Chair in Neurosurgery and Head of the University of Minnesota Medical School Department of Neurosurgery shows more than a quarter of patients with recurrent high-grade glioma, a form of brain cancer, were alive more than three years after treatment. "Given the deadly nature of this disease, three-year survival is rarely reported in the recurrent
Biotechnology cancer Cell Therapy Clinical Trials Immunotherapies

Fred Hutch researchers engineer complex immunotherapy that may target relapsing leukemia

Researchers at Fred Hutchinson Cancer Research Center and the University of Washington have developed a novel way to genetically engineer T cells that may be effective for treating and preventing leukemia relapse. The findings, published online in the journal Blood, provide the basis for launching a first-in-human clinical trial of this new immunotherapy, which relies on engineered T-cell receptors, or TCRs. This immunotherapy represents a different method of genetic engineering
cancer Clinical Trials Immunotherapies

KEYNOTE-040 evaluates pembrolizumab in head and neck cancer

Immunotherapy with the checkpoint inhibitor pembrolizumab may be a better option than standard treatments for patients whose head and neck cancer has spread, or recurred after an initial round of chemotherapy, according to results of the Keynote-040 trial presented at the ESMO 2017 Congress in Madrid. (1) Although the 19% improvement in overall survival among patients treated with pembrolizumab did not meet the prespecified difference for statistical significance, it was
cancer Cell Therapy

A new HER2 mutation, a clinical trial and a promising diagnostic tool for metastatic breast cancer

There is a group of metastatic breast cancers that has the HER2 gene amplified - the cells have many copies of it - which leads to enhanced activity of the product enzyme, a tyrosine kinase. HER2 has been established as a therapeutic target in breast cancer, and breast cancers in which the HER2 gene is not amplified do not, in general, respond to HER2-directed therapeutic approaches. A few years ago,
Biotechnology cancer Cell Therapy Clinical Trials

A new HER2 mutation, a clinical trial and a promising diagnostic tool for metastatic breast cancer

There is a group of metastatic breast cancers that has the HER2 gene amplified - the cells have many copies of it - which leads to enhanced activity of the product enzyme, a tyrosine kinase. HER2 has been established as a therapeutic target in breast cancer, and breast cancers in which the HER2 gene is not amplified do not, in general, respond to HER2-directed therapeutic approaches. A few years ago,